Replies to post #339521 on Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

Could it be that "HE" actually received MORE than what was reported ????????

IB, I'm no kind of specialist in business strategy, so it may be that I haven't had the correct Risk Analysis seminar yet. Maybe someone with that training could help me understand.

Elite 2019
1. Trace money in bank.
2. Trace income.
3. No access to capital.
4. Historic low share price.
5. Going concern.
6. $20M burn rate.
7. Discontinued 5 opioid ANDA's worth up to $50M/yr due to concern of being sued for legal behavior in a highly-regulated industry.
8. Sold off 4 opioid ANDAs for a fraction of the cost to develop them.




For me, the decisions that Nasrat made about opioids are ludicrous. The whole scenario is so bizarre that it has the APPEARANCE OF IMPROPRIETY, especially considering the secretive private pharma that was supposedly shut down years ago.



Nasrat says: I had to dump the opioids before I started acting so illegally and egregiously that the company is sued. I just couldn't be trusted to commercialize and sell opioids like the majority of manufacturers who haven't been sued. The private deals I am making with my other secret company are completely unrelated.